- Alter MJ, Hadler SC, Judson FN, Mares A, Alexander WJ, Hu PY, Miller JK, Moyer LA, Fields HA, Bradley DW, et al. Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection. JAMA 1990;264: 2231–2235.
- Brown RS Jr, Gaglio PJ. Scope of worldwide hepatitis C problem. Liver Transpl 2003;9: S10–S13.
- Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, Margolis HS. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341: 556–562.
- Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting the future complications of hepatitis C in the United States. Liver Transpl 2003;9: 331–338.
- Koretz RL, Stone O, Mousa M, Gitnick GL. Non-A, non-B posttransfusion hepatitis—a decade later. Gastroenterology 1985;88 (5 Pt 1): 1251–1254.
- Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology 1991;14: 969–974.
- El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 2002;36 (5 Suppl 1): S74–S83.
- UNOS Scientific Registry. Primary liver disease of liver transplant recipients, 1991 and 1992. UNOS Update 1993;9: 27.
- Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358: 958–965.
- Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347: 975–982.
- Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 2000;31: 777–782.
- National Center for Health Statistics. Plan and Operation of the Third National Health and Nutrition Examination Survey, 1988–94. Vital and Health Statistics. Series 1, No. 32 (DHHS Publication No. 94-1308). Washington, DC: Government Printing Office, July 1994.
- US Census Bureau. State and county demographics. Available at http://www.census.gov/main/www/cen2000.html; accessed November 10, 2004.
- Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of interferon alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997;127: 855–865.
- Seeff LB, Buskell-Bales Z, Wright EC, Durako SJ, Alter HJ, Iber FL, Hollinger FB, Gitnick G, Knodell RG, Perrillo RP, et al; The National Heart, Lung, and Blood Institute Study Group. Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med 1992;327: 1906–1911.
- Tong MJ, El-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332: 1463–1466.
- Roffi L, Redaelli A, Colloredo G, Minola E, Donada C, Picciotto A, Riboli P, Del Poggio P, Rinaldi G, Paris B, Fornaciari G, Giusti M, Marin R, Morales R, Sangiovanni A, Belloni G, Pozzi M, Poli G, Mascoli N, Corradi C, Pioltelli P, Scalori A, Mancia G. Outcome of liver disease in a large cohort of histologically proven chronic hepatitis C: influence of HCV genotype. Eur J Gastroenterol Hepatol 2001;13: 501–506.
- Tanaka K, Sakai H, Hashizume M, Hirohata T. A long-term follow-up study on risk factors for hepatocellular carcinoma among Japanese patients with liver cirrhosis. Jpn J Cancer Res 1998;89: 1241–1250.
- El-Serag HB, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med 2000;160: 3227–3230.
- Baillargeon J, Wu H, Kelley MJ, Grady J, Linthicum L, Dunn K. Hepatitis C seroprevalence among newly incarcerated inmates in the Texas correctional system. Public Health 2003;117: 43–48.
- Grieco E. The foreign born from Mexico in the United States. Migration Information Source 2003 (October 1). Available at http://www.migrationinformation.org/feature/display.cfm?ID=163; accessed November 10, 2004.
- El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340: 745–750.
- Nair S, Shiv Kumar K, Thuluvath PJ, Shivakumar KS, Shiva Kumar K. Mortality from hepatocellular and biliary cancers: changing epidemiological trends. Am J Gastroenterol 2002;97: 167–171.
- Darby SC, Ewart DW, Giangrande PL, Spooner RJ, Rizza CR, Dusheiko GM, Lee CA, Ludlam CA, Preston FE; UK Haemophilia Centre Directors' Organisation. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. Lancet 1997;350: 1425–1431.
- Kasahara A, Hayashi N, Mochizuki K, Takayanagi M, Yoshioka K, Kakumu S, Iijima A, Urushihara A, Kiyosawa K, Okuda M, Hino K, Okita K; Osaka Liver Disease Study Group. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology 1998;27: 1394–1402.
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 18, 2005 - Issue 1